We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNSF.L Regulatory News (NSF)

  • There is currently no data for NSF

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Update on Current Status and Regulatory matters

28 Sep 2022 07:05

RNS Number : 9163A
Non-Standard Finance PLC
28 September 2022
 

Non-Standard Finance plc

('Non-Standard Finance', 'NSF', the 'Company' or the 'Group')

Update on Current Status and Regulatory matters

 

28 September 2022

 

· This update provides a summary of the current status of the Group. More detailed information is provided in the Unaudited Half Year Results to 30 June 2022 announcement which is also published today.

· Despite promising operational performance, the Group continues to be loss making, and for the March 2022 and June 2022 quarter end covenant tests, the loan to value ratio was higher than the level permitted under the covenant. The Group, through negotiations with its lenders, has obtained a short-term waiver which means the loan to value covenant will not be formally tested, and therefore no covenant breach or event of default will arise, until the Group provides its compliance certificates for the March 2022 and June 2022 quarter dates. The date on which the Group is required to supply these compliance certificates has been extended until 5 October 2022, with a mechanism for this date to be extended further with lender support.

· In order to remedy the situation, a capital raise (the 'Capital Raise') is needed. To enable a Capital Raise, certainty is needed as to the extent of redress liabilities. The Directors have therefore decided to pursue the use of a court-based process (the 'Process'), such as a scheme of arrangement or restructuring plan, in relation to its redress liabilities. A successful Process will allow the Group to proceed with its planned capital raise. If successful, the proceeds of the Capital Raise will be used to fund a cash pot which will be available to finance the payment of redress liabilities to affected customers and to strengthen the Group's balance sheet and underpin future growth. Prior to the Capital Raise, further short-term waivers from lenders will be required and are likely to be dependent on positive progress of the Process.

· Although it is not expected that the Process will provide for redress claims to be paid in full, the Directors believe that the Process is in the best interests of customers with redress claims. Without the Process, the Directors believe a Capital Raise would not be successful and therefore insolvency is the most likely outcome, in which there would likely be no payment of redress liabilities.

· A key objective of the Process will be to treat all affected customers equally. Although the independent review of the Group's branch-based lending division carried out in 2021 identified no systemic issues requiring redress, as the branch-based and guarantor loans divisions both trade out of the same legal entity, the Process will encompass potential claims from both divisions in order to ensure equitable treatment of customers.

· The Group is actively engaged with the FCA, the FOS, as well as Alchemy and the Group's lenders, regarding the Process. It has appointed an independent chairperson to chair a committee of customers with redress claims, who will review the terms of the Process on behalf of affected customers.

· Further details of the Process will be announced in due course. The Process will be subject to satisfying the statutory creditor approval requirements and the sanction of the Court.

· We are engaging with the FCA with respect to the business' plan to rely on DISP 1.6.2R(2), pursuant to which, Everyday Loans is entitled to place a temporary hold on the processing of customer complaints.

· Plans for the Capital Raise remain subject to successful completion of the Process and the continued support of Alchemy and other key shareholders as well as the Group's lenders.

· Without the successful completion of the Capital Raise, the Group remains balance sheet insolvent and the Group's ability to remain a going concern is subject to material uncertainties. However, the Directors continue to believe there is a reasonable prospect of resolving this position through the Process and the Capital Raise.

· The Directors of NSF plc are working with key stakeholders on an alternative transaction to be implemented if the Process is successful, but the ensuing Capital Raise is unsuccessful which would preserve the branch-based lending business as a going concern. In this scenario, it is expected that the same cash pot would be available to finance the payment of redress liabilities as if the Capital Raise had completed. However, there would be a material risk of the Company and certain other members of the Group entering insolvency and as a result there would be no recovery for the Company's shareholders. 

 

 

28 September 2022

 

 

 

 

 

 

 

For more information:

Non-Standard Finance plc

Jono Gillespie, Group Chief Executive Officer

Sarah Day, Chief ESG Officer & Company Secretary

+44 (0) 20 3869 9020

H/Advisors Maitland

Neil Bennett

Finlay Donaldson

+44 (0) 20 7379 5151

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDSESEFWEESELU
Date   Source Headline
10th Jul 20237:00 amRNSNotice of Delisting
7th Jul 20238:06 amRNSSuspension of Trading in Ordinary Shares
5th Jul 20233:18 pmRNSUpdate on Delisting and Suspension of Shares
23rd Jun 20232:51 pmRNSFiling of Annual General Meeting Resolutions
23rd Jun 20232:49 pmRNSResult of AGM
23rd Jun 20237:00 amRNSUpdate on Scheme, Delisting & Directorate Change
23rd May 20237:00 amRNSStandard form for notification of major holdings
18th May 20237:00 amRNSProposed Recapitalisation & Directorate Change 
28th Apr 20235:51 pmRNSReplacement: Update on scheme of arrangement
28th Apr 20233:33 pmRNSUpdate on scheme of arrangement
28th Apr 20238:21 amRNSAudited full year results to 31 December 2022
14th Apr 20237:00 amRNSProposed Release of Debt and Directorate Change
4th Apr 20234:14 pmRNSDirector/PDMR Shareholding
29th Mar 20234:35 pmRNSPrice Monitoring Extension
23rd Mar 20234:35 pmRNSPrice Monitoring Extension
17th Mar 20237:39 amRNSLaunch of Scheme & Proposed Recapitalisation
17th Mar 20237:00 amRNSScheme of Launch & Proposed Recapitalisation
13th Feb 20237:00 amRNS2022 Trading Statement
4th Jan 202310:15 amRNSDirector/PDMR Shareholding
3rd Jan 20234:40 pmRNSSecond Price Monitoring Extn
3rd Jan 20234:35 pmRNSPrice Monitoring Extension
4th Oct 20224:40 pmRNSSecond Price Monitoring Extn
4th Oct 20224:35 pmRNSPrice Monitoring Extension
29th Sep 20225:50 pmRNSDirector/PDMR Shareholding
29th Sep 20224:40 pmRNSSecond Price Monitoring Extn
29th Sep 20224:37 pmRNSPrice Monitoring Extension
28th Sep 20227:05 amRNSUpdate on Current Status and Regulatory matters
28th Sep 20227:05 amRNSUnaudited Half Year Results to 30 June 2022
27th Jul 20224:41 pmRNSSecond Price Monitoring Extn
27th Jul 20224:36 pmRNSPrice Monitoring Extension
22nd Jul 20224:40 pmRNSSecond Price Monitoring Extn
22nd Jul 20224:35 pmRNSPrice Monitoring Extension
19th Jul 20224:41 pmRNSSecond Price Monitoring Extn
19th Jul 20224:35 pmRNSPrice Monitoring Extension
6th Jul 20224:40 pmRNSSecond Price Monitoring Extn
6th Jul 20224:36 pmRNSPrice Monitoring Extension
4th Jul 20224:16 pmRNSDirector/PDMR Shareholding
15th Jun 20223:25 pmRNSFunding facilities update
26th May 20224:42 pmRNSFilings of AGM Resolutions
26th May 20222:49 pmRNSResults of Annual General Meeting
29th Apr 202212:00 pmRNSDirectorate Change
29th Apr 20227:00 amRNSAudited full year results to 31 December 2021
29th Apr 20227:00 amRNSAudited full year results to 31 December 2021
1st Apr 20224:40 pmRNSSecond Price Monitoring Extn
1st Apr 20224:35 pmRNSPrice Monitoring Extension
29th Mar 20229:26 amRNSDirector/PDMR Shareholding
17th Mar 20224:41 pmRNSSecond Price Monitoring Extn
17th Mar 20224:36 pmRNSPrice Monitoring Extension
16th Mar 20224:41 pmRNSSecond Price Monitoring Extn
16th Mar 20224:36 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.